Skip to content
Open access · OA via OpenAlex

Highlights from Recent Cancer Literature

Authors not listed

Cancer Research · 2013

Abstract

Schumacher D, Strilic B, Sivaraj KK, Wettschureck N, Offermanns S. Platelet-derived nucleotides promote tumor-cell transendothelial migration and metastasis via P2Y2 receptor. Cancer Cell 2013;24:130–37.Platelets are often abnormal in cancer. A raised platelet count in a routine blood test can be a sign of an occult malignancy, and depletion of platelets reduces metastases in many experimental cancer models. Schumacher and colleagues reveal a novel mechanism by which platelets facilitate metastases independent of their role in clotting. They found that adenine nucleotides released from tumor-cell activated platelets resulted in opening of the endothelial barrier and stimulating endothelial transmigration of tumor cells with the platelet-derived ATP acting through the ATP receptor P2Y2 (P2RY2) on the endothelial cells. Blockade of either ATP release from platelets or P2Y2 receptor on endothelial cells had a profound effect on experimental metastases of the transplantable LLC or B16 mouse tumor cell lines. A general blockade of platelet activation might reduce metastasis, but it could also increase the risk of bleeding. These results suggest that inhibiting the P2Y2 receptor might inhibit platelet-promoted metastasis without disabling the normal functions of platelets, especially as the P2Y2 knockout mice were relatively healthy. Recent reports of epidemiologic studies in large patient cohorts show that long-term low-dose aspirin reduces the risk of metastasis. Because aspirin is known to inhibit platelet function, the current study could provide one explanation for this effect.Ghajar CM, Peinado H, Mori H, Matei IR, Evason KJ, Brazier H et al. The perivascular niche regulates breast tumor dormancy. Nat Cell Biol 2013;15:807–17.One of the perplexing questions of cancer biology is why some patients develop metastatic disease years, even decades, after initial diagnosis and treatment. In many human and experimental cancers, evidence exists to show that malignant cells disseminate early, maybe even before the primary tumor is apparent. What keeps these malignant cells dormant, and what eventually stimulates them to proliferate and form metastases? Ghajar and colleagues provide one plausible explanation. They reasoned that as breast cancer cells disseminate in the blood to such sites as the lung and bone marrow, endothelial cells and factors deposited in their basement membrane may be involved in malignant cell dormancy. In a series of experiments in mice, orthotopic models of human microvasculature, and zebrafish, Ghahar and colleagues demonstrated how stable microvasculature constitutes a dormant niche, whereas sprouting neovasculature stimulates micrometastatic outgrowth. In murine breast cancer models they found dormant malignant cells in the microvasculature of the lung, bone marrow, and brain. Using organotypic models of lung and bone marrow microvasculature, they identified thrombospondin-1 (TSP-1; THBS1), as an endothelium-derived tumor suppressor. If the vessels were sprouting, TSP-1 levels were decreased. Moreover, tumor growth was accelerated around sprouting tips of blood vessels. These areas were rich in such tumor promoters as active TGF-β1 and periostin. Hence, preserving vascular homeostasis may be critical to maintaining dormancy of disseminated tumor cells. Whether this is true for other cancers and if there is evidence for this phenomenon in human cancer patients remain to be seen. However, this early work begins to suggest possible ways of preventing relapse.Masiero M, Simões FC, Han HD, Snell C, Peterkin T, Bridges E, et al. A core human primary tumor angiogenesis signature identifies the endothelial orphan receptor ELTD1 as a key regulator of angiogenesis. Cancer Cell 2013;24:1–13.Despite extensive preclinical studies and recognition that angiogenesis is critical for tumor formation and progression, clinical evidence to date shows limited efficacy of antiangiogenic therapies. Thus, a better understanding of the biology and potential therapeutic targets that regulate the process of angiogenesis may be required if new therapies are to be successful. To address this issue, Masiero and colleagues studied gene expression profiles from over 1,000 samples to identify regulators of angiogenesis in human tumors. They used, as initial “seeds,” a set of genes known to be important in cancer and also involved in angiogenesis. Using data from head and neck squamous carcinoma, breast cancer, and clear cell renal cell carcinoma, they observed that gene signatures of angiogenesis differ among these tumors, but that a set of 43 angiogenesis-associated genes was common to these tumor types. Then they studied the modulation of these 43 genes in response to antiangiogenic therapies, including bevacizumab and DBZ (a γ-secretase inhibitor/NOTCH pathway inhibitor) using preclinical models. They found that DBZ treatment regulated their 43-gene signature in their experimental model. Using cultured endothelial cells stimulated with DLL4 (to activate NOTCH signaling) they further narrowed the gene list to those reciprocally regulated by DBZ and DLL4. One of these genes was ELTD1, an orphan G-protein–coupled receptor on which the authors directed their focus. Immunohistochemical analysis for ELTD1 showed increased staining in tumor-associated endothelial cells in a variety of cancer types. Increased staining was found to be associated with improved clinical outcome in renal cancer and ovarian cancer, which is consistent with the fact that the hypoxic state is associated with treatment resistance. As supporting evidence, they noted that ELDT1 expression levels were inversely associated with a hypoxia gene signature and with the hypoxia inducible gene CA9, which is expressed in the vasculature of zebrafish embryos. Moreover, with the use of antisense morpholinos, severe vascular defects became evident upon gene silencing. In animal tumor models, silencing of ELTD1 blocked sprouting of endothelial cell

◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:

Read at source →

Provenance

Source
OpenAlex
DOI
10.1158/0008-5472.5299.73.17
Canonical
link ↗
Fetched
2026-10-13 MST

Cite this

APA
Anonymous. (2013). Highlights from Recent Cancer Literature. <em>Cancer Research</em>. https://doi.org/10.1158/0008-5472.5299.73.17
Vancouver
Anonymous. Highlights from Recent Cancer Literature. Cancer Research. 2013. doi:10.1158/0008-5472.5299.73.17.
BibTeX
@article{anon2013Highli, title = {Highlights from Recent Cancer Literature}, author = {Anonymous}, journal = {Cancer Research}, year = {2013}, doi = {10.1158/0008-5472.5299.73.17}, }

Research neighborhood

References, citing works, and semantically nearest findings. Click a node to open it.

Related findings